Copyright © 2025 Shenyang Dasan Pharmaceutical Technology Co., Ltd.
Home
2025

  • Levetiracetam Oral Solution, Teicoplanin for Injection, and Roxatidine Acetate Hydrochloride, participated in commissioned R&D, received registration approvals

2023

  • Established an off-campus internship base with the College of Life Science and Engineering, Shenyang University

  • The company officially joined the "Liaoning Shangyao North Pharmaceutical High-End Formulation Industry-University-Research Alliance"

  • Pharmaceutical manufacturing license obtained: Cetirizine Hydrochloride Injection accepted by NMPA

  • Collaborated with Shanghai Jiao Tong University on an excipient-related research project, with results published in an internationally renowned journal

2021

  • Received the first import approval for Roxatidine for Injection

  • "Levetiracetam Oral Solution" underwent on-site inspection by NMPA

  • Actively participated in social welfare activities and was awarded the title of "Caring Enterprise"

  • "Captopril Tablets" underwent on-site inspection by NMPA

  • Reached a strategic cooperation agreement with Beijing Leading Pharmaceutical

2019

  • Received the first approval for generic drug quality and efficacy consistency evaluation

  • The company became a National High-Tech Enterprise

  • The company's project management system was officially launched

  • Roxatidine Acetate Hydrochloride Sustained-Release Capsules passed formal BE study

  • The company's first generic drug consistency evaluation project was submitted

  • Established a practice education base with Shenyang Pharmaceutical University

2017

  • Laboratory area expanded to 1,000 sqm

  • Established a pharmaceutical internship base with Xinglin College, Liaoning University of Traditional Chinese Medicine

  • Completion of R&D SOPs compliant with ICH requirements; chromatographic network management system launched

2015

  • Signed the first technical cooperation contract and began providing pharmaceutical technology services nationwide

  • Entered the pharmaceutical CRO service sector for generic drugs in China

  • Developed Roxatidine sustained-release pellets and Dabigatran etexilate tartrate pellets

2024

  • Shenyang DASAN 10th Anniversary Celebration

  • Signed strategic cooperation agreement with Liaoning Oxiran Pharmaceutical Co., Ltd.

  • Two research results from formulation projects participated in by the company were published in Chinese core journals

  • Reached CMO cooperation agreements with Liaoning Daewoong and Haisco

  • Established an employment training base with Yanbian University

  • Passed pharmaceutical manufacturing license scope expansion (Telmisartan Amlodipine Tablets) with zero deficiencies

  • Anhui Heyida DASAN Pharmaceutical Co., Ltd. was established

  • Pharmaceutical manufacturing license scope expansion: Telmisartan Amlodipine Tablets

  • Signed strategic cooperation agreement with Shangyao North Pharmaceutical

  • Established an employment training base with Liaoning University

2022

  • Underwent registration inspection for the Northeast Pharmaceutical project

  • Omeprazole Enteric-Coated Capsules project was approved with exemption from registration inspection

  • Reached strategic cooperation with Liaoning Daewoong Pharmaceutical

2020

  • The company introduced equity investment from Korean partner Dasan Pharmaceutical and became a Sino-foreign joint venture

  • The industry-recognized challenging project "Omeprazole Enteric-Coated Capsules" passed the formal BE study

  • The first generic Roxatidine Acetate Hydrochloride Sustained-Release Capsules in China, developed using Korean coating technology introduced by the company, was accepted for registration

2018

  • Submitted two consistency evaluation projects

  • Laboratory quality management system was established

  • Laboratory management system was established, achieving standardized management

2016

  • Launched strategic cooperation with Northeast Pharmaceutical Group

  • R&D system SOP and SMP were established

  • Expanded into the field of generic drug quality and efficacy consistency evaluation

  • GMP-compliant data management system went live

2014

  • Formulation R&D center in Shenyang commenced operations

  • Introduced equity investment from Shanghai Gaozhun Pharmaceutical Technology Co., Ltd., gaining support for API development

  • Reached a technical cooperation agreement with Dasan Medichem (Korea) to develop products suitable for the Chinese market

  • The company was registered and established